scholarly article | Q13442814 |
P356 | DOI | 10.1038/S41375-019-0569-7 |
P698 | PubMed publication ID | 31471562 |
P50 | author | Sigrid S Skånland | Q58206316 |
Deepak B Thimiri Govinda Raj | Q61133617 | ||
Geir Erland Tjønnfjord | Q90232036 | ||
P2093 | author name string | Kjetil Taskén | |
Ludvig A Munthe | |||
Andrea Cremaschi | |||
Johanne U Hermansen | |||
Henrik Bendiksen | |||
P2860 | cites work | BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia | Q26765624 |
The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia | Q28075504 | ||
Chronic lymphocytic leukaemia | Q30249196 | ||
National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data | Q31147343 | ||
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies | Q33419789 | ||
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL | Q33714712 | ||
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 | ||
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia | Q34009003 | ||
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML | Q34042250 | ||
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
Chronic lymphocytic leukemia therapy: new targeted therapies on the way | Q37113544 | ||
The B-cell receptor pathway: a critical component of healthy and malignant immune biology | Q38232484 | ||
Targeting B Cell Signaling in Chronic Lymphocytic Leukemia | Q38654101 | ||
Ibrutinib for treatment of chronic lymphocytic leukemia | Q38765015 | ||
The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia | Q38797084 | ||
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity | Q39056302 | ||
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia | Q41848521 | ||
Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells | Q42317487 | ||
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. | Q51280033 | ||
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. | Q52582128 | ||
Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia. | Q54261746 | ||
Chronic lymphocytic leukaemia | Q56270980 | ||
Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL | Q56514276 | ||
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma | Q57471770 | ||
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 | Q58776981 | ||
Cryopreservation of primary B cells minimally influences their signaling responses | Q59792926 | ||
Targeted Therapies in CLL: Monotherapy Versus Combination Approaches | Q90395831 | ||
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia | Q90569013 | ||
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia | Q91735722 | ||
Ibrutinib and Venetoclax for First-Line Treatment of CLL | Q92374811 | ||
P433 | issue | 2 | |
P921 | main subject | biomarker | Q864574 |
ibrutinib | Q5984881 | ||
P304 | page(s) | 478-487 | |
P577 | publication date | 2019-08-30 | |
P1433 | published in | Leukemia | Q6534498 |
P1476 | title | An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL | |
P478 | volume | 34 |
Search more.